See more : Spacenet Enterprises India Limited (SPCENET.NS) Income Statement Analysis – Financial Results
Complete financial analysis of Zhejiang Starry Pharmaceutical Co.,Ltd. (603520.SS) income statement, including revenue, profit margins, EPS and key performance metrics. Get detailed insights into the financial performance of Zhejiang Starry Pharmaceutical Co.,Ltd., a leading company in the Drug Manufacturers – Specialty & Generic industry within the Healthcare sector.
- Lazard Global Total Return and Income Fund, Inc. (LGI) Income Statement Analysis – Financial Results
- Entasis Therapeutics Holdings Inc. (ETTX) Income Statement Analysis – Financial Results
- Sekur Private Data Ltd. (SKUR.CN) Income Statement Analysis – Financial Results
- CleanSpace Holdings Limited (CSX.AX) Income Statement Analysis – Financial Results
- Mind Medicine (MindMed) Inc. (MMDCF) Income Statement Analysis – Financial Results
Zhejiang Starry Pharmaceutical Co.,Ltd. (603520.SS)
Industry: Drug Manufacturers - Specialty & Generic
Sector: Healthcare
Website: https://www.starrypharm.com
About Zhejiang Starry Pharmaceutical Co.,Ltd.
Zhejiang Starry Pharmaceutical Co.,Ltd. engages in the research and development, production, and sale of X-CT non-ionic contrast agents and fluoroquinolones drugs and intermediates in China and internationally. Its contrast agent products include iohexol, iohexol hydrolysate, iohexol iodide, ioversol, iopamidol, iomeprol, iopromide, cybeclamine, iodixanol, gadopentetic acid dimeglumine, and glutamate; and fluoroquinolones products comprise levofloxacin, levofloxacin hydrochloride, levoflurane, levofluorocarboxylic acid, pazufloxacin, and pazufloxacin mesylate. The company was founded in 1997 and is based in Xianju, China.
| Metric | 2023 | 2022 | 2021 | 2020 | 2019 | 2018 | 2017 | 2016 | 2015 | 2014 | 2013 | 2012 | 2011 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Revenue | 2.20B | 2.13B | 2.00B | 1.37B | 1.31B | 890.47M | 710.94M | 672.95M | 695.66M | 658.48M | 685.90M | 574.71M | 506.58M |
| Cost of Revenue | 1.66B | 1.62B | 1.25B | 765.73M | 749.66M | 530.06M | 444.29M | 416.24M | 437.17M | 451.02M | 503.52M | 432.63M | 345.20M |
| Gross Profit | 533.33M | 512.45M | 747.98M | 601.36M | 559.18M | 360.41M | 266.65M | 256.70M | 258.49M | 207.47M | 182.39M | 142.08M | 161.38M |
| Gross Profit Ratio | 24.29% | 24.04% | 37.40% | 43.99% | 42.72% | 40.47% | 37.51% | 38.15% | 37.16% | 31.51% | 26.59% | 24.72% | 31.86% |
| Research & Development | 134.56M | 132.61M | 124.58M | 87.84M | 77.78M | 66.13M | 53.13M | 49.06M | 40.39M | 31.52M | 31.36M | 27.86M | 0.00 |
| General & Administrative | 51.24M | 68.80M | 52.82M | 70.35M | 49.70M | 44.53M | 27.30M | 23.59M | 18.24M | 17.92M | 13.07M | 14.87M | 58.51M |
| Selling & Marketing | 91.28M | 70.81M | 22.60M | 11.54M | 13.14M | 11.55M | 9.71M | 16.34M | 11.56M | 9.88M | 9.99M | 11.32M | 9.33M |
| SG&A | 142.52M | 139.61M | 75.42M | 81.89M | 62.85M | 56.08M | 37.01M | 39.93M | 29.80M | 27.80M | 23.07M | 26.19M | 67.84M |
| Other Expenses | 207.05M | 68.33M | 67.84M | 66.33M | 72.42M | -8.11M | -3.38M | 5.52M | -307.74K | 7.51M | 4.58M | 5.12M | 959.00K |
| Operating Expenses | 484.14M | 340.56M | 267.84M | 236.07M | 213.04M | 175.27M | 137.32M | 141.13M | 124.94M | 99.16M | 84.54M | 78.66M | 69.87M |
| Cost & Expenses | 2.15B | 1.96B | 1.52B | 1.00B | 962.70M | 705.33M | 581.61M | 557.37M | 562.11M | 550.17M | 588.06M | 511.29M | 415.08M |
| Interest Income | 7.55M | 9.70M | 5.70M | 3.92M | 1.95M | 3.04M | 670.20K | 777.22K | 423.31K | 711.98K | 599.48K | 619.09K | -0.30 |
| Interest Expense | 108.65M | 92.60M | 73.82M | 92.04M | 82.61M | 64.99M | 34.40M | 24.60M | 36.86M | 32.00M | 27.60M | 24.93M | 13.55M |
| Depreciation & Amortization | 179.55M | 168.93M | 159.09M | 129.09M | 112.05M | 87.36M | 74.06M | 66.56M | 57.78M | 50.94M | 43.54M | 36.23M | 24.12M |
| EBITDA | 327.92M | 312.87M | 628.70M | 524.49M | 417.01M | 270.67M | 211.99M | 189.85M | 188.01M | 162.79M | 144.94M | 102.87M | 115.62M |
| EBITDA Ratio | 14.93% | 14.68% | 32.00% | 38.57% | 33.61% | 30.91% | 30.05% | 28.26% | 27.51% | 25.20% | 21.40% | 18.12% | 23.18% |
| Operating Income | 138.93M | 152.43M | 399.77M | 401.06M | 330.97M | 126.83M | 106.87M | 93.42M | 93.68M | 75.02M | 70.70M | 37.29M | 77.24M |
| Operating Income Ratio | 6.33% | 7.15% | 19.99% | 29.34% | 25.29% | 14.24% | 15.03% | 13.88% | 13.47% | 11.39% | 10.31% | 6.49% | 15.25% |
| Total Other Income/Expenses | -83.60M | -217.83M | -45.73M | 9.76M | -109.08M | -55.92M | -3.38M | -18.21M | -36.77M | -27.98M | -23.67M | -22.46M | 172.92K |
| Income Before Tax | 55.33M | -65.40M | 395.39M | 303.70M | 221.90M | 118.72M | 103.49M | 97.45M | 93.37M | 79.85M | 73.81M | 41.72M | 77.41M |
| Income Before Tax Ratio | 2.52% | -3.07% | 19.77% | 22.22% | 16.95% | 13.33% | 14.56% | 14.48% | 13.42% | 12.13% | 10.76% | 7.26% | 15.28% |
| Income Tax Expense | 798.82K | 6.52M | 65.62M | 50.10M | 38.98M | 23.18M | 22.07M | 21.54M | 19.91M | 12.82M | 11.01M | 6.72M | 10.08M |
| Net Income | 44.23M | -71.93M | 323.75M | 238.73M | 170.33M | 93.68M | 83.12M | 76.12M | 68.94M | 67.70M | 63.66M | 35.78M | 67.57M |
| Net Income Ratio | 2.01% | -3.37% | 16.19% | 17.46% | 13.01% | 10.52% | 11.69% | 11.31% | 9.91% | 10.28% | 9.28% | 6.23% | 13.34% |
| EPS | 0.13 | -0.21 | 0.95 | 0.71 | 0.52 | 0.29 | 0.25 | 0.25 | 0.28 | 0.27 | 0.26 | 0.15 | 0.27 |
| EPS Diluted | 0.13 | -0.21 | 0.95 | 0.71 | 0.52 | 0.29 | 0.25 | 0.25 | 0.28 | 0.27 | 0.26 | 0.15 | 0.27 |
| Weighted Avg Shares Out | 340.25M | 342.25M | 341.94M | 334.22M | 328.58M | 327.87M | 329.28M | 307.17M | 245.69M | 247.71M | 246.02M | 245.44M | 247.21M |
| Weighted Avg Shares Out (Dil) | 340.25M | 342.25M | 341.94M | 334.22M | 328.58M | 327.87M | 330.54M | 307.17M | 245.69M | 247.71M | 246.02M | 245.48M | 247.21M |
Source: https://incomestatements.info
Category: Stock Reports